Cargando…
Surgical treatment of malignant involvement of the inferior vena cava
BACKGROUND: Resection and replacement of the inferior vena cava to remove malignant disease is a formidable procedure. The purpose of this review is to describe our experience with regard to patient selection, operative technique, and early and late outcome. METHODS: The authors retrospectively revi...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1574333/ https://www.ncbi.nlm.nih.gov/pubmed/16911808 http://dx.doi.org/10.1186/1477-7800-3-19 |
_version_ | 1782130288496738304 |
---|---|
author | Castelli, Patrizio Caronno, Roberto Piffaretti, Gabriele Tozzi, Matteo Lomazzi, Chiara Dionigi, Gianlorenzo Boni, Luigi Dionigi, Renzo |
author_facet | Castelli, Patrizio Caronno, Roberto Piffaretti, Gabriele Tozzi, Matteo Lomazzi, Chiara Dionigi, Gianlorenzo Boni, Luigi Dionigi, Renzo |
author_sort | Castelli, Patrizio |
collection | PubMed |
description | BACKGROUND: Resection and replacement of the inferior vena cava to remove malignant disease is a formidable procedure. The purpose of this review is to describe our experience with regard to patient selection, operative technique, and early and late outcome. METHODS: The authors retrospectively reviewed a 12-year series of 11 patients; there were 10 males, with a mean age 57 ± 13 years (range 27–72) who underwent caval thrombectomy and/or resection for primary (n = 9) or recurrent (n = 2) vena cava tumours. Tumour location and type, clinical presentation, the segment of vena cava treated, graft patency, and tumour recurrence and survival data were collected. Late follow-up data were available for all patients. Graft patency was determined before hospital discharge and in follow-up by CT scan or ultrasonography. More than 80% of patients had symptoms from their caval involvement. The most common pathologic diagnosis was renal cell carcinoma (n = 6), and hepatocarcinoma (n = 2). In all but 2 patients, inferior vena cava surgical treatment was associated with multivisceral resection, including extended nephrectomy (n = 5), resection of neoplastic mass (n = 3), major hepatic resection (n = 2), and adrenal gland resection (n = 1). Prosthetic repair was performed in 5 patients (45%). RESULTS: There were no early deaths. Major complications occurred in 1 patient (9%). Mean length of stay was 16 days. Late graft thrombosis or infection did not occur. The mean follow-up was 22.7 months (range 6–60). There have been no other late graft-related complications. All late deaths were caused by the progression of malignant disease and the actuarial survival rate was 100% at 1 year. Mean survival was 31 months (median 15). CONCLUSION: Aggressive surgical management may offer the only chance for cure or palliation for patients with primary or secondary caval tumours. Our experience confirms that vena cava surgery for tumours may be performed safely with low graft-related morbidity and good patency in carefully selected patients. |
format | Text |
id | pubmed-1574333 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-15743332006-09-23 Surgical treatment of malignant involvement of the inferior vena cava Castelli, Patrizio Caronno, Roberto Piffaretti, Gabriele Tozzi, Matteo Lomazzi, Chiara Dionigi, Gianlorenzo Boni, Luigi Dionigi, Renzo Int Semin Surg Oncol Research BACKGROUND: Resection and replacement of the inferior vena cava to remove malignant disease is a formidable procedure. The purpose of this review is to describe our experience with regard to patient selection, operative technique, and early and late outcome. METHODS: The authors retrospectively reviewed a 12-year series of 11 patients; there were 10 males, with a mean age 57 ± 13 years (range 27–72) who underwent caval thrombectomy and/or resection for primary (n = 9) or recurrent (n = 2) vena cava tumours. Tumour location and type, clinical presentation, the segment of vena cava treated, graft patency, and tumour recurrence and survival data were collected. Late follow-up data were available for all patients. Graft patency was determined before hospital discharge and in follow-up by CT scan or ultrasonography. More than 80% of patients had symptoms from their caval involvement. The most common pathologic diagnosis was renal cell carcinoma (n = 6), and hepatocarcinoma (n = 2). In all but 2 patients, inferior vena cava surgical treatment was associated with multivisceral resection, including extended nephrectomy (n = 5), resection of neoplastic mass (n = 3), major hepatic resection (n = 2), and adrenal gland resection (n = 1). Prosthetic repair was performed in 5 patients (45%). RESULTS: There were no early deaths. Major complications occurred in 1 patient (9%). Mean length of stay was 16 days. Late graft thrombosis or infection did not occur. The mean follow-up was 22.7 months (range 6–60). There have been no other late graft-related complications. All late deaths were caused by the progression of malignant disease and the actuarial survival rate was 100% at 1 year. Mean survival was 31 months (median 15). CONCLUSION: Aggressive surgical management may offer the only chance for cure or palliation for patients with primary or secondary caval tumours. Our experience confirms that vena cava surgery for tumours may be performed safely with low graft-related morbidity and good patency in carefully selected patients. BioMed Central 2006-08-16 /pmc/articles/PMC1574333/ /pubmed/16911808 http://dx.doi.org/10.1186/1477-7800-3-19 Text en Copyright © 2006 Castelli et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Castelli, Patrizio Caronno, Roberto Piffaretti, Gabriele Tozzi, Matteo Lomazzi, Chiara Dionigi, Gianlorenzo Boni, Luigi Dionigi, Renzo Surgical treatment of malignant involvement of the inferior vena cava |
title | Surgical treatment of malignant involvement of the inferior vena cava |
title_full | Surgical treatment of malignant involvement of the inferior vena cava |
title_fullStr | Surgical treatment of malignant involvement of the inferior vena cava |
title_full_unstemmed | Surgical treatment of malignant involvement of the inferior vena cava |
title_short | Surgical treatment of malignant involvement of the inferior vena cava |
title_sort | surgical treatment of malignant involvement of the inferior vena cava |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1574333/ https://www.ncbi.nlm.nih.gov/pubmed/16911808 http://dx.doi.org/10.1186/1477-7800-3-19 |
work_keys_str_mv | AT castellipatrizio surgicaltreatmentofmalignantinvolvementoftheinferiorvenacava AT caronnoroberto surgicaltreatmentofmalignantinvolvementoftheinferiorvenacava AT piffarettigabriele surgicaltreatmentofmalignantinvolvementoftheinferiorvenacava AT tozzimatteo surgicaltreatmentofmalignantinvolvementoftheinferiorvenacava AT lomazzichiara surgicaltreatmentofmalignantinvolvementoftheinferiorvenacava AT dionigigianlorenzo surgicaltreatmentofmalignantinvolvementoftheinferiorvenacava AT boniluigi surgicaltreatmentofmalignantinvolvementoftheinferiorvenacava AT dionigirenzo surgicaltreatmentofmalignantinvolvementoftheinferiorvenacava |